Alzheimer disease pharmacologic treatment and treatment research

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 2, 2013, Pages 339-357

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVAGACESTAT; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; PLACEBO; RIVASTIGMINE; SEMAGACESTAT; TACRINE;

ADVERSE OUTCOME; ALZHEIMER DISEASE; ANOREXIA; CLINICAL EFFECTIVENESS; CONFUSION; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG MARKETING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; LIVER TOXICITY; LONG TERM CARE; MUSCLE CRAMP; NAUSEA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; CHOLINESTERASE INHIBITORS; DRUG APPROVAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84876375022     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000429180.60095.d0     Document Type: Review

References (80)

1. Bartus R, Dean R, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217(4558):408-414.
2. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30(2):113-121.
3. Schneider LS. Antidementia drugs. In: Sadock BJ, Sadock MD, Ruiz P, editors. Comprehensive textbook of psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2009:4119-4130.
4. McArthur RA, Gray J, Schreiber R. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. Curr Opin Investig Drugs 2010;11(7):740-760.
5. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD001190.
6. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363(9427):2105-2115.
7. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
8. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318(7184):633-638.
9. Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69(4 suppl 1):S14-S22.
10. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;(1):CD001747.
11. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009;169(9):867-873.
12. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32(7):1234-1251.
13. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
14. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S51-S56.
15. Schneider LS, Insel PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurology 2011;68(1):58-66.
16. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70(22):2024-2035.
17. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6(6):501-512.
18. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-2388.
19. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4(11):e338.
20. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006;(3):CD006104.
21. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-1341.
22. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-324.
23. van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21(2): 136-143.
24. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14(8):704-715.
25. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008;13(1):97-107.
26. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5(1):83-89.
27. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154.
28. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68(8):991-998.
29. Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 1999;38(9):1253-1259.
30. Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010;176(2): 870-880.
31. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80(6):600-607.
32. Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009;1(2):7.
33. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63(1): 49-54.
34. Schneider LS. Open-label extension studies and misinformation. Arch Neurol 2006;63(7):1036; author reply 1036-1037.
35. Alvarez XA, Cacabelos R, Sampedro C, et al. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res 2011;8(5):583-591.
36. Schneider LS. Ginkgo biloba extract and preventing Alzheimer disease. JAMA 2008;300(19):2306-2308.
37. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009(1): CD003120.
38. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005; 2(5):541-551.
39. McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008;23(12):1222-1230
40. Institute for Quality and Efficiency in Health Care. Alzheimer's disease: only a few therapies provide proof of benefit to patients. www.iqwig.de/index. 948.en. html?random=667c6a. Updated April 30, 2010. Accessed January 3, 2013.
41. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300(19):2253- 2262.
42. Vellas B, Andrieu S, Ousset PJ, et al. The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006; 67(9 suppl 3):S6-S11.
43. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 2008;70(19 pt 2): 1809-1817.
44. U.S. Food and Drug Administration. Guidance for industry: frequently asked questions about medical foods. www.fda. gov/Food/ GuidanceComplianceRegulatory Information/GuidanceDocuments/MedicalFoods/ ucm054048.htm. Updated July 27, 2011. Accessed February 8, 2013.
45. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009; 6(1):31.
46. Scheltens P, Twisk JWR, Blesa R, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 2012;31(1): 225-236.
47. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148(5): 379-397.
48. Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006;21(1):17-28.
49. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10(1):iii-iv, ix-xi, 1-160.
50. Watson SM. NDA # 20-690 Aricept (donepezil hydrochloride) tablets. 2010 warning letters and untitled letters to pharmaceutical companies. www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Enforcement ActivitiesbyFDA/WarningLettersandNoticeof ViolationLetterstoPharmaceutical Companies/UCM201238.pdf. Dated February 4, 2010. Accessed January 3, 2013.
51. Abrams T. NDA 20-823/21-025: Exelon (rivastigmine tartrate) capsules and oral solution: MACMIS ID #14943. Warning letter. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054180. pdf. Accessed February 12, 2012.
52. Lindner MD, McArthur RA, Deadwyler S, et al. Development, optimization and use of preclinical behavioral models to maximize the productivity of drug discovery for Alzheimer's disease. In: McArthur RA, Borsini F, eds. Animal and translational models for CNS drug discovery. San Diego, CA: Academic Press, 2008:93-157.
53. Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006;174(8):1099-1105.
54. Atri A, Shaughnessy L, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22(3): 209-221.
55. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51(7):937-944.
56. Schneider LS, Qizilbash N. Delay in nursing home placement with donepezil. J Am Geriatr Soc 2004;52(6):1024-1026.
57. Sona A, Zhang P, Ames D, et al. Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr 2011;24(2):1-8.
58. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63(2):214-219.
59. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005;11(3):231-251.
60. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366(10):893-903.
61. Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med 2012;366(10):957-959.
62. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21(5):813-824.
63. Campbell N, Ayub A, Boustani MA, et al. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. Clin Interv Aging 2008;3(4):719-728.
64. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357(14):1382-1392.
65. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One 2012; 7(5):e35185.
66. Schneider LS. Issues in design and conduct of clinical trials for cognitive-enhancing drugs. In: McArthur RA, Borsini F, eds. Animal and translational models for CNS drug discovery. San Diego, CA: Academic Press, 2008:21-76.
67. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2): S13-S21.
68. Golde TE, Schneider LS, Koo EH. Anti-A therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011; 69(2):203-213.
69. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-388.
70. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353- 356.
71. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-α peptide clearance. Sci Transl Med 2011;3(89):89ra57.
72. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-223.
73. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-[beta] load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-372.
74. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64(9):1553-1562.
75. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24): 2061-2070.
76. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2011;69(2): 198-207.
77. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114(512):797-811.
78. Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 2011; 121(5):589-595.
79. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2011;8(6):666-677.
80. Fuentes P, Catalan J. A clinical perspective: anti taus treatment in Alzheimer's disease. Curr Alzheimer Res 2011;8(6): 686-688.